RAS: Past, Present, and Future, Volume 153 (Hardcover)

Advances in Cancer Research, volume 153 provides a timely review of the biology, biochemistry, and current approaches to therapeutically target the RAS oncoprotein, the most frequently mutated oncogene family in human cancers. 2021 saw the approval of the first direct RAS inhibitor (sotorasib) for use in treating non-small cell lung cancers harboring KRAS(G12C) mutations. The successful approval and use of this drug highlights that the once "undruggable" RAS is indeed pharmacologically tractable. This volume provides an overview of efforts to develop additional approaches to therapeutically target oncogenic RAS. In addition, the reader will find excellent reviews on the history and research efforts to understand the biochemistry and oncogenic activity of RAS in human cancers.

General

Imprint:	Academic Press Inc
Country of origin:	United States
Series:	Advances in Cancer Research
Release date:	February 2022
First published:	2022
Volume editors:	John P. O'Bryan • Gary Piazza
Dimensions:	229 x 152mm (L x W)
Format:	Hardcover
Pages:	356
ISBN-13:	978-0-12-824485-2
Categories:	Books > Science & Mathematics > Biology, life sciences > Cellular biology > General Books > Science & Mathematics > Biology, life sciences > Microbiology (non-medical) > Virology Books > Medicine > Clinical & internal medicine > Diseases & disorders > Immunology > General Books > Science & Mathematics > Biology, life sciences > Life sciences: general issues > Genetics (non-medical) > General
LSN:	0-12-824485-2
Barcode:	9780128244852

Is the information for this product incomplete, wrong or inappropriate? Let us know about it.

Does this product have an incorrect or missing image? Send us a new image.

Is this product missing categories? Add more categories.

Review This Product

No reviews yet - be the first to create one!